OncoMatch/Clinical Trials/NCT02693535
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Is NCT02693535 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lymphoma, non-hodgkin.
Treatment: Palbociclib · Sunitinib · Temsirolimus · Trastuzumab and Pertuzumab · Vemurafenib and Cobimetinib · Regorafenib · Olaparib · Nivolumab and Ipilimumab · Abemaciclib · Talazoparib · Atezolizumab and Talazoparib · Tucatinib plus Trastuzumab Subcutaneous (SC) · Futibatinib · Dabrafenib plus Trametinib · Fam-Trastuzumab Deruxtecan-Nxki (TDxD) — The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Multiple Myeloma
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^6/µl; Hemoglobin > 9.0 g/dl; Platelets > 75,000/µl
Kidney function
Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
Liver function
Total bilirubin < 2.0 mg/dl, except in patients with Gilbert's Syndrome; AST/ALT < 2.5 x ULN (or < 5 x ULN in patients with known hepatic metastases)
Patients must have acceptable organ function as defined below. 1. Absolute neutrophil count ≥ 1.5 x 10^6/µl 2. Hemoglobin > 9.0 g/dl 3. Platelets > 75,000/µl 4. Total bilirubin < 2.0 mg/dl, except in patients with Gilbert's Syndrome 5. AST/ALT < 2.5 x ULN (or < 5 x ULN in patients with known hepatic metastases) 6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Comprehensive Cancer Center · Birmingham, Alabama
- Cancer Treatment Centers of America-Phoenix · Phoenix, Arizona
- Sutter Auburn · Auburn, California
- Sutter Alta Bates · Berkeley, California
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify